Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Evofem Biosciences, Inc. (EVFM) had Revenue of $19.36M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$19.36M
Net Income	$-8.96M
Cost of Goods Sold	$3.83M
Gross Profit	$15.53M
Operating Expenses	$27.04M
Operating Income	$-7.68M
Non-Operating Income/Expense	$-1.18M
Pre-Tax Income	$-8.86M
Normalized Pre-Tax Income	$-8.86M
Income after Taxes	$-8.86M
Income from Continuous Operations	$-8.86M
Consolidated Net Income/Loss	$-8.86M
Normalized Income after Taxes	$-8.86M
EBIT	$-7.68M
EBITDA	$-7.03M
Weighted-Average Shares Outstanding (Basic)	75.20M
Weighted-Average Shares Outstanding (Diluted)	75.20M
Earnings per Share (EPS) (Basic)	$-0.12
Earnings per Share (EPS) (Diluted)	$-0.12
Balance Sheet Financials
Current Assets	$13.61M
Property, Plant, and Equipment	$0.46M
Long-Term Assets	$10.18M
Total Assets	$23.79M
Current Liabilities	$80.45M
Long-Term Debt	--
Long-Term Liabilities	$9.82M
Total Liabilities	$90.26M
Common Equity	$-71.26M
Tangible Shareholders Equity	$-76.07M
Shareholders Equity	$-66.47M
Common Shares Outstanding	113.36M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-3.88M
Cash Flow from Investing Activities	$-0.57M
Cash Flow from Financial Activities	$4.62M
Beginning Cash	$0.58M
End Cash	$0.74M
Increase/Decrease in Cash	$0.16M
Stock-Based Compensation	$0.85M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	-0.69
Gross Margin	80.20%
Operating Margin	-39.64%
EBIT Margin	-39.64%
EBITDA Margin	-36.29%
Pre-Tax Profit Margin	-45.76%
Profit Margin	-46.30%
Free Cash Flow	$-4.45M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.81
Inventory Turnover	2.43
Receiveable Turnover	1.97
Days Sales in Receivables	185.34
Return on Equity	12.43%
Return on Tangible Equity	11.65%
Return on Assets	-37.24%
Return on Investments	13.33%
Book Value Per Share	$-0.59
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.05

Data from Zacks Investment Research, Inc.